Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert J Ossenkoppele

Showing results (91-100 of 193) with videos related to

Pageof 20
Sort By:
Leukemia Research|April 20, 2019
Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemiaBijan Moshaver, Rolf F Wouters, Angèle Kelder, et al.
Blood|July 5, 2007
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cellsAnna van Rhenen, Guus A M S van Dongen, Angèle Kelder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation studyDavid R Colnot, Gert J Ossenkoppele, Jan C Roos, et al.
Haematologica|December 4, 2008
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcomeMartine E D Chamuleau, Arjan A van de Loosdrecht, Corine J Hess, et al.
Journal of Clinical Pathology|July 14, 2006
Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCLJoost C van Galen, Jettie J F Muris, Joost J Oudejans, et al.
Cytometry. Part B, Clinical Cytometry|January 18, 2013
A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid originWillemijn van den Ancker, Theresia M Westers, David C de Leeuw, et al.
Haematologica|November 12, 2009
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responsesMarvin M van Luijn, Martine E D Chamuleau, James A Thompson, et al.
Annals of Hematology|March 7, 2007
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older ageMarry M van den Heuvel-Eibrink, Bronno van der Holt, Alan K Burnett, et al.
British Journal of Haematology|May 8, 2013
A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignanciesGert J Ossenkoppele, Bob Lowenberg, Pierre Zachee, et al.
Blood|November 30, 2006
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)Leo F Verdonck, Annelise Notenboom, Daphne D de Jong, et al.
Pageof 20

Showing results (91-100 of 193) with videos related to

Sort By:
Pageof 20
Leukemia Research|April 20, 2019
Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemiaBijan Moshaver, Rolf F Wouters, Angèle Kelder, et al.
Blood|July 5, 2007
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cellsAnna van Rhenen, Guus A M S van Dongen, Angèle Kelder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2002
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation studyDavid R Colnot, Gert J Ossenkoppele, Jan C Roos, et al.
Haematologica|December 4, 2008
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcomeMartine E D Chamuleau, Arjan A van de Loosdrecht, Corine J Hess, et al.
Journal of Clinical Pathology|July 14, 2006
Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCLJoost C van Galen, Jettie J F Muris, Joost J Oudejans, et al.
Cytometry. Part B, Clinical Cytometry|January 18, 2013
A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid originWillemijn van den Ancker, Theresia M Westers, David C de Leeuw, et al.
Haematologica|November 12, 2009
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responsesMarvin M van Luijn, Martine E D Chamuleau, James A Thompson, et al.
Annals of Hematology|March 7, 2007
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older ageMarry M van den Heuvel-Eibrink, Bronno van der Holt, Alan K Burnett, et al.
British Journal of Haematology|May 8, 2013
A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignanciesGert J Ossenkoppele, Bob Lowenberg, Pierre Zachee, et al.
Blood|November 30, 2006
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)Leo F Verdonck, Annelise Notenboom, Daphne D de Jong, et al.
Pageof 20